BENITIONSClinical Trial Intelligence

Prophylactic Risedronate for Patients With Peripheral Lung Tumors Treated With SBRT

第2相 完了 NCT03861091

対象疾患Lung Neoplasm
第2相
スポンサーWake Forest University Health Sciences
ステータス完了
参加者数84 名
介入(薬剤)risedronate, Matching placebo
開始日2019年7月12日
完了日2022年3月2日
結果公開日2023年7月14日

概要

This is a double blind randomized controlled study investigating the efficacy of a single dose of 150 mg risedronate (a bone anti-resorptive) vs a single dose of placebo given prior to SBRT for peripheral lung tumors that are within 2 cm of the chest wall. Our hypothesis is that the use of a single dose of 150 mg risedronate will eliminate or greatly reduce the rapid bone loss that occurs with radiation induced early osteoclast recruitment/activation. Patients will be given either a single dose of 150 mg risedronate or placebo at the time of their treatment mapping "simulation" CT scan. Typically, radiation treatments begin at 1 - 3 weeks following this mapping scan, as each treatment plan requires detailed physics calculations and quality assurance checks. All CT imaging referenced below is performed as a routine standard of care surveillance and is necessary for cancer treatment follow-up. These chest CT scans that are utilized in this research protocol would be performed every 3 months regardless of inclusion on this trial.

Changes in Mean Cortical Thickness

At baseline and at 3 months post radiation · percent change in mm cortical thickne

Risedronate4.24 ± 3.04 percent change in mm cortical thickne
Matching Placebo7.14 ± 2.93 percent change in mm cortical thickne

BENITIONS で見る ClinicalTrials.gov の原文を見る

同じ疾患の他の治験

すべての治験

このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。